



**Pharmaceutical  
Division**

Miles Inc.  
400 Morgan Lane  
West Haven, CT 06516  
203 937-2000

December 14, 1987

Robert R. Green, M.D.  
45 South Main Street  
Heber City, UT 84032

Dear Dr. Green:


Miles is pleased to introduce Cipro® Tablets (ciprofloxacin HCl/Miles), a revolutionary oral antimicrobial with parenteral-like potency. Totally synthetic, Cipro® is structurally unrelated to penicillins, cephalosporins, or tetracyclines.

Cipro® is the most potent of a new quinolone class of oral antimicrobial agents<sup>1-3</sup>--and the only quinolone indicated for infections beyond the urinary tract.\* In clinical trials, Cipro® achieved a favorable response in over 94% of infection sites, including infections of the lower respiratory tract, urinary tract, skin/skin structure, and bones and joints; and in infectious diarrhea.<sup>4</sup>

Cipro® is the most potent oral agent against methicillin-resistant Staphylococcus aureus<sup>1</sup> and "...the most potent anti-pseudomonas agent yet...."<sup>5\*</sup> Cipro® also has high in vitro activity against most of the Enterobacteriaceae, including Escherichia coli, Proteus, Klebsiella, and Enterobacter species, and Serratia marcescens; Campylobacter species; Haemophilus influenzae; Legionella species; coagulase-negative Staphylococcus species; and Streptococcus pneumoniae, Streptococcus pyogenes, and Enterococcus species.\* The enclosed Prescribing Information contains a complete list of the organisms indicated for each infection.

Low minimal inhibitory concentrations (MICs),<sup>6\*</sup> rapid bactericidal action,<sup>7</sup> and high tissue and fluid levels<sup>8-11\*\*</sup> achieved with Cipro® Tablets allow for oral treatment of many infections that previously were treatable only with injectable antibiotics.

Cipro® Tablets provide parenteral-like potency without the discomfort, inconvenience, and potential complications of injectable antibiotics. Cipro® is well tolerated. In clinical trials, the most commonly observed adverse reactions, drug related or not, have been nausea (5.2%), diarrhea (2.3%), vomiting (2.0%), abdominal pain/discomfort (1.7%), headache (1.2%), rash (1.1%), and restlessness (1.1%). Other adverse reactions were each reported in fewer than 1% of patients.<sup>4</sup>



Ran Tucker

Wasatch

Wawe

Wm. Bethers - 1173  
372

Bowers

P 866

ace Bethers

arvon Daniels

B & H Museum

Lee Kames

Ford Smith on  
Gilderness  
Rhodes

Bro Brigham

Cold

Jorgensen

ADD  
**RIDAURA.**  
BRAND OF  
auranofin

for

**BENEFIT BEYOND THE NSAIDs  
in Rheumatoid Arthritis**

See back for complete prescribing information.

ADD  
**RIDAURA.**  
BRAND OF  
auranofin

for

**BENEFIT BEYOND THE NSAIDs  
in Rheumatoid Arthritis**

See back for complete prescribing information.